<SEC-DOCUMENT>0001602474-26-000004.txt : 20260730
<SEC-HEADER>0001602474-26-000004.hdr.sgml : 20260730
<ACCEPTANCE-DATETIME>20260730160433
ACCESSION NUMBER:		0001602474-26-000004
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20260514
FILED AS OF DATE:		20260730
DATE AS OF CHANGE:		20260730

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Dalal Anupam
		CENTRAL INDEX KEY:			0001602474
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38560
		FILM NUMBER:		261223235

	MAIL ADDRESS:	
		STREET 1:		88 KEARNY STREET, SUITE 1800
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94108

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Whitehawk Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001422142
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				611547850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		2 HEADQUARTERS PLAZA
		STREET 2:		EAST BUILDING, 11TH FLOOR
		CITY:			MORRISTOWN
		STATE:			NJ
		ZIP:			07960
		BUSINESS PHONE:		551-321-2234

	MAIL ADDRESS:	
		STREET 1:		2 HEADQUARTERS PLAZA
		STREET 2:		EAST BUILDING, 11TH FLOOR
		CITY:			MORRISTOWN
		STATE:			NJ
		ZIP:			07960

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Aadi Bioscience, Inc.
		DATE OF NAME CHANGE:	20210826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Aerpio Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20170316

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZETA ACQUISITION CORP II
		DATE OF NAME CHANGE:	20071227
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4-07302026_080728.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0609</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2026-05-14</periodOfReport>

    <issuer>
        <issuerCik>0001422142</issuerCik>
        <issuerName>Whitehawk Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>WHWK</issuerTradingSymbol>
        <issuerForeignTradingSymbol></issuerForeignTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001602474</rptOwnerCik>
            <rptOwnerName>Dalal Anupam</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerNonUSAddressFlag>false</rptOwnerNonUSAddressFlag>
            <rptOwnerStreet1>C/O WHITEHAWK THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>2 HEADQUARTERS PLAZA, EAST BUILDING, 11T</rptOwnerStreet2>
            <rptOwnerCity>MORRISTOWN</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>07960</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
            <isOfficer>false</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2026-05-14</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>1275510</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>3.92</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>4685912</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See footnote</value>
                    <footnoteId id="F1"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>1130</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value></value>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>4.16</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2026-06-12</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>38040</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <value>2036-06-12</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>38040</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>38040</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value></value>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Consists of (i) 3,538,288 shares held by Acuta Capital Fund, LP (&quot;Acuta Capital&quot;) and (ii) 1,147,624 shares held by Acuta Opportunity Fund, LP. (&quot;Acuta Opportunity Fund&quot;). Acuta Capital Partners, LLC (&quot;Acuta Partners&quot;) is the general partner of each of Acuta Capital and Acuta Opportunity Fund. The Reporting Person is the Chief Investment Officer and Managing Member of Acuta Partners. The Reporting Person has voting and investment authority over all of the shares held by each of Acuta Capital and Acuta Opportunity Fund. Each of Acuta Partners and the Reporting Person disclaim beneficial ownership of the shares of common stock held by each of Acuta Capital and Acuta Opportunity Fund except to the extent of their pecuniary interest therein.</footnote>
        <footnote id="F2">Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. &quot;Date of Grant&quot; shall mean June 12, 2026.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Stephen Rodin, as Attorney-in-Fact</signatureName>
        <signatureDate>2026-07-30</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
